European Commission Consults On GMP For Authorized Medicines
This article was originally published in SRA
Executive Summary
A fourth consultation document, on proposed new good manufacturing practice (GMP) rules for medicines with a marketing authorization, has been launched by the European Commission as part of its drive to implement the provisions of the Clinical Trials Regulation1.